Quinolinone compound as well as preparation method and application thereof

Abstract

The invention discloses a quinolinone compound as well as a preparation method and application thereof. Specifically, the quinolinone compound as shown in the general formula (I) provided by the invention has an antagonistic effect on a 5-hydroxytryptamine transporter and good regulation activity on a 5-hydroxytryptamine 1A (5-HT1A) receptor, can be used for treating various central nervous system diseases, and does not cause central or peripheral side effects caused by complete excitation of the 5-HT1A receptor. In addition, the compound disclosed by the invention is high in activity and oral bioavailability, has the characteristics of low drug dose, small toxic and side effects and the like, and has a curative effect on diseases in the field of central nervous systems. # imgabs0 #

Description

Technical Field

[0001] The present invention belongs to the field of pharmaceutical chemistry. Specifically, the present invention relates to a quinolinone compound represented by general formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, a preparation method thereof, a pharmaceutical composition and its application in preparing drugs for central nervous system diseases. Background Art

[0002] With the rapid development of society, people's pace of life and pressure are increasing day by day. Mental illness has become a disease that seriously affects human health and has brought serious consequences to patients and their families. Due to factors such as susceptibility to suicide, lack of medical care, and a higher risk of complications, the average life expectancy of patients with mental illness is shortened. A large number of studies have shown that mental illness is related to abnormal functions of multiple central neurotransmitters and receptors, such as monoamine transmitters in the brain, especially the dopamine (DA) system and the 5-hydroxytryptamine (5-HT) system, which are closely related to normal mental activities of the human body. When the DA and 5-HT systems are dysfunctional, it is easy to cause the occurrence of a variety of neuropsychiatric diseases, such as schizophrenia, depression, neuropathic pain, mania, anxiety, Parkinson's disease, etc.

[0003] The 5-HT transporter is an important target for antidepressant and antianxiety drugs. Existing SSRIs (selective 5-HT reuptake inhibitors) drugs selectively inhibit the 5-HT transporter and increase the 5-HT concentration in the synaptic cleft, thereby exerting antidepressant and antianxiety effects. 1A The 5-HT receptor is the most widespread 5-HT receptor subtype in the brain and is involved in many brain-related diseases, including depression, anxiety, and cognitive impairment. 1A The combined use of 5-HT receptor partial agonists (such as buspirone and tandurone) and 5-HT transporter inhibitors can enhance the antidepressant effect of 5-HT transporter inhibitors, possibly because the two drugs can work synergistically to increase the 5-HT 1A Therefore, compounds that have both of these effects will have good research and development prospects. Such compounds can take effect quickly and may be more effective than 5-HT alone. 1A Receptor agonists and SSRIs are significant. The new drug vilazodone launched in the United States in 2011 is 5-HT 1A A dual-target drug that stimulates 5-HT receptors and inhibits 5-HT transporters. The drug takes effect in one week and has no adverse reactions such as sexual dysfunction.

[0004] Therefore, finding compounds with balanced regulation of multiple targets including 5-HT transporters and 5-HT receptors is beneficial to better regulate the balance of multiple neurotransmitters in the brain, regulate the DA / 5-HT system, and thus better treat diseases in the central nervous system.

[0005] In view of this, the present invention is proposed. Summary of the invention

[0006] Purpose of the Invention

[0007] The present invention aims to provide a class of 5-hydroxytryptamine transporter antagonists and 5-hydroxytryptamine 1A (5-HT 1A ) receptors have good regulatory activity.

[0008] An object of the present invention is to provide a quinolinone compound represented by general formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof.

[0009] Another object of the present invention is to provide a method for preparing the quinolinone compound represented by the general formula (I).

[0010] Another object of the present invention is to provide a pharmaceutical composition comprising a therapeutically effective amount of the compound represented by general formula (I), its stereoisomers or pharmaceutically acceptable salts thereof.

[0011] Another object of the present invention is to provide the use of the quinolinone compound represented by the general formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, and the above-mentioned pharmaceutical composition in the preparation of drugs for preventing and / or treating central nervous system diseases.

[0012] Technical Solution

[0013] According to one aspect of the present invention, there is provided a quinolinone compound represented by the general formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof:

[0014]

[0015] in:

[0016] X on the benzene ring is a halogen, preferably F;

[0017] Y is NH, O or S, preferably O or S;

[0018] W is CH, CH2 or O;

[0019] represents a single bond or a double bond;

[0020] When W is CH2 or O, the represents a single bond; when W is CH, represents a double bond;

[0021] Z on the heterocyclic ring is hydrogen, cyano, amino C1-C6 alkanoyl or amino C1-C6 alkyl substituted amino C1-C6 alkyl acyl, preferably, Z is hydrogen, cyano, amino C1-C4 alkanoyl or amino C1-C4 alkanoyl substituted C1-C4 alkyl (preferably N-methylcarbamoyl), more preferably hydrogen, cyano, carbamoyl or N-methylcarbamoyl;

[0022] When connected with R6, R7, R8, R9 When it represents a single bond, R6, R7, R8, and R9 are each independently selected from hydrogen, deuterium, halogen, methyl, ethyl, hydroxyl, amino, or acetylamino, preferably hydrogen, deuterium, halogen, or hydroxyl; or one of R6 and R7 and one of R8 and R9 and the two carbon atoms connected thereto form a 3-6-membered carbocyclic ring, preferably a 3-membered carbocyclic ring, and the other two are as defined above;

[0023] When connected with R6, R7, R8, R9 When it represents a double bond, R6 and R8 are each independently selected from hydrogen, deuterium, halogen, methyl, ethyl, hydroxyl, amino or acetylamino, preferably hydrogen, deuterium, halogen, and R7 and R9 do not exist; or R6 and R8 and the two carbon atoms connected thereto form a 3-6 membered carbocyclic ring, preferably a 4-6 membered carbocyclic ring, and R7 and R9 do not exist;

[0024] Provided that the following compounds are not included:

[0025] 1) 7-(2-(4-(6-fluorobenzothiophen-4-yl)piperazin-1-yl)ethyl)-quinolin-2(1H)-one;

[0026] 2) 7-(2-(4-(6-fluorobenzothiophen-4-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one.

[0027] In some preferred embodiments, X is F.

[0028] In some preferred embodiments, Y is O or S.

[0029] In some preferred embodiments, Z is hydrogen, cyano, amino C1-C4 acyl or amino C1-C4 alkanoyl substituted by C1-C4 alkyl (preferably N-methylcarbamoyl); preferably, Z is hydrogen, cyano, N-methylcarbamoyl or carbamoyl.

[0030] In some preferred embodiments, R6, R7, R8, R9 are connected represents a single bond, and R6, R7, R8, and R9 are each independently selected from hydrogen, deuterium, halogen or hydroxyl.

[0031] In some preferred embodiments, R6, R7, R8, R9 are connected represents a double bond, R6 and R8 are each independently selected from hydrogen, deuterium, halogen or hydroxyl, and R7 and R9 do not exist.

[0032] In some preferred embodiments, R6, R7, R8, R9 are connected It represents a single bond, R6 and R8 and the two carbon atoms connected to them form a 3-membered carbon ring; R7 and R9 are hydrogen or deuterium.

[0033] In some preferred embodiments, X is F and Y is O.

[0034] In some preferred embodiments,

[0035] represents a single bond or a double bond;

[0036] X is halogen; Y is O or S; W is CH, CH2 or O; Z is hydrogen, cyano, carbamoyl or carbamoyl substituted with C1-C6 alkyl;

[0037] When connected with R6, R7, R8, R9 When it represents a single bond, R6, R7, R8, and R9 are each independently selected from hydrogen, deuterium, halogen, methyl, ethyl, hydroxyl, amino, or acetylamino; or one of R6 and R7 and one of R8 and R9 and the two carbon atoms connected thereto form a 3-6 membered carbocyclic ring, and the other two are as defined above;

[0038] When connected with R6, R7, R8, R9 When it represents a double bond, R6 and R8 are each independently selected from hydrogen, deuterium, halogen, methyl, ethyl, hydroxyl, amino or acetylamino, preferably hydrogen, deuterium, halogen, R7 and R9 do not exist; or R6 and R8 and the two carbon atoms connected to them form a 4-6 membered carbocyclic ring.

[0039] In some preferred embodiments,

[0040] represents a single bond or a double bond;

[0041] X is F; Y is O; W is CH, CH2 or O; Z is hydrogen, cyano, carbamoyl or carbamoyl substituted with C1-C6 alkyl;

[0042] When connected with R6, R7, R8, R9 When it represents a single bond, R6, R7, R8, and R9 are each independently selected from hydrogen, deuterium, halogen, methyl, ethyl, hydroxyl, amino, or acetylamino; or one of R6 and R7 and one of R8 and R9 and the two carbon atoms connected thereto form a 3-6 membered carbocyclic ring, and the other two are as defined above;

[0043] When connected with R6, R7, R8, R9 When it represents a double bond, R6 and R8 are each independently selected from hydrogen, deuterium, halogen, methyl, ethyl, hydroxyl, amino or acetylamino, preferably hydrogen, deuterium, halogen, R7 and R9 do not exist; or R6 and R8 and the two carbon atoms connected to them form a 4-6 membered carbocyclic ring.

[0044] In some embodiments, the quinolinone compound represented by general formula (I) is selected from the following structures:

[0045]

[0046] in, Z, R6, R7, R8 and R9 are as defined above.

[0047] In some preferred embodiments, the quinolinone compound represented by general formula (I) is selected from the following structures:

[0048]

[0049]

[0050] in, Z, R6, R7, R8 and R9 are as defined above.

[0051] In some more preferred embodiments, the quinolinone compound represented by the general formula (I) is selected from (I-1), (I-2), and (I-5).

[0052] In some most preferred embodiments, the quinolinone compound represented by general formula (I) is selected from the following structures:

[0053]

[0054] in, Z, R6, R7, R8 and R9 are as defined above.

[0055] Among the quinolinone compounds represented by the general formula (I), their stereoisomers or pharmaceutically acceptable salts thereof, the following compounds or pharmaceutically acceptable salts thereof are most preferred:

[0056] (1) 7-(2-(4-(6-fluorobenzofuran-4-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one;

[0057]

[0058] (2) 7-(2-(4-(6-fluoro-2,3-dihydrobenzofuran-4-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one;

[0059]

[0060] (3) 7-(2-(4-(5-fluorobenzofuran-7-yl)piperazin-1-yl)ethyl)quinolin-2(1H)-one;

[0061]

[0062] (4) 7-(2-(4-(5-fluoro-2,3-dihydrobenzofuran-7-yl)piperazin-1-yl)ethyl)quinolin-2(1H)-one;

[0063]

[0064] (5) 7-(2-(4-(5-fluoro-2,3-dihydrobenzofuran-7-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one;

[0065]

[0066] (6) 7-(2-(4-(5-fluorobenzofuran-7-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one;

[0067]

[0068] (7) 7-(2-(4-(6-fluoro-2,3-dihydrobenzofuran-4-yl)piperazin-1-yl)ethyl)quinolin-2(1H)-one;

[0069]

[0070] (8) 7-(2-(4-(6-fluorobenzofuran-4-yl)piperazin-1-yl)ethyl)quinolin-2(1H)-one;

[0071]

[0072] (9) 5-(2-(4-(6-fluorobenzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-1,1a,3,7b-tetrahydro-2H-cyclopropyl[c]quinolin-2-one;

[0073]

[0074] (10) 5-(2-(4-(5-fluorobenzo[b]thiophen-7-yl)piperazin-1-yl)ethyl)-1,1a,3,7b-tetrahydro-2H-cyclopropyl[c]quinolin-2-one;

[0075]

[0076] (11) 7-(2-(4-(5-fluorobenzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one;

[0077]

[0078] (12) 7-(2-(4-(7-fluorobenzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one;

[0079]

[0080] (13) 7-(2-(4-(4-fluorobenzo[b]thiophen-7-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one;

[0081]

[0082] (14) 7-(2-(4-(6-fluorobenzo[b]thiophen-7-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one;

[0083]

[0084] (15) 7-(2-(4-(5-fluorobenzo[b]thiophen-7-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one;

[0085]

[0086] (16) 7-(2-(4-(5-fluorobenzo[b]thiophen-7-yl)piperazin-1-yl)ethyl)quinolin-2(1H)-one;

[0087]

[0088] (17) 7-(2-(4-(6-fluorobenzofuran-4-yl)piperazin-1-yl)ethyl)-4-hydroxy-3,4-dihydroquinolin-2(1H)-one;

[0089]

[0090] (18) 7-(2-(4-(6-fluoro-2,3-dihydrobenzofuran-4-yl)piperazin-1-yl)ethyl)-4-hydroxy-3,4-dihydroquinolin-2(1H)-one;

[0091]

[0092] (19) 7-(2-(4-(6-fluorobenzofuran-4-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one-3,4-d2;

[0093]

[0094] (20) 7-(2-(4-(6-fluorobenzofuran-4-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one-3,3-d2;

[0095]

[0096] (21) 7-(2-(4-(6-fluoro-2,3-dihydrobenzofuran-4-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one-3.4-d2;

[0097]

[0098] (22) 7-(2-(4-(6-fluoro-2,3-dihydrobenzofuran-4-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one-3,3-d2;

[0099]

[0100] (23) 6-fluoro-4-(4-(2-(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)ethyl)piperazin-1-yl)benzo[b]thiophene-2-carboxamide;

[0101]

[0102] (24) 6-fluoro-4-(4-(2-(2-oxo-1,2-dihydroquinolin-7-yl)ethyl)piperazin-1-yl)benzo[b]thiophene-2-carboxamide;

[0103]

[0104] (25) 6-fluoro-4-(4-(2-(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)ethyl)piperazin-1-yl)benzofuran-2-carboxamide;

[0105]

[0106] (26) 6-fluoro-4-(4-(2-(2-oxo-1,2-dihydroquinolin-7-yl)ethyl)piperazin-1-yl)benzofuran-2-carboxamide;

[0107]

[0108] (27) 6-fluoro-N-methyl-4-(4-(2-(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)ethyl)piperazin-1-yl)benzo[b]thiophene-2-carboxamide;

[0109]

[0110] (28) 7-(2-(4-(5-fluorobenzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)quinolin-2(1H)-one;

[0111]

[0112] (29) 7-(2-(4-(7-fluorobenzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-quinolin-2(1H)-one;

[0113]

[0114] (30) 7-(2-(4-(4-Fluorobenzo[b]thiophen-7-yl)piperazin-1-yl)ethyl)-quinolin-2(1H)-one;

[0115]

[0116] (31) 7-(2-(4-(6-fluorobenzo[b]thiophen-7-yl)piperazin-1-yl)ethyl)-quinolin-2(1H)-one;

[0117]

[0118] (32) 6-fluoro-N-methyl-4-(4-(2-(2-oxo-1,2-dihydroquinolin-7-yl)ethyl)piperazin-1-yl)benzo[b]thiophene-2-carboxamide;

[0119]

[0120] (33) 5-fluoro-7-(4-(2-(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)ethyl)piperazin-1-yl)benzo[b]thiophene-2-carboxamide;

[0121]

[0122] (34) 5-fluoro-7-(4-(2-(2-oxo-1,2-dihydroquinolin-7-yl)ethyl)piperazin-1-yl)benzo[b]thiophene-2-carboxamide;

[0123]

[0124] (35) 5-fluoro-7-(4-(2-(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)ethyl)piperazin-1-yl)benzofuran-2-carboxamide;

[0125]

[0126] (36) 5-fluoro-7-(4-(2-(2-oxo-1,2-dihydroquinolin-7-yl)ethyl)piperazin-1-yl)benzofuran-2-carboxamide;

[0127]

[0128] (37) 5-fluoro-7-(4-(2-(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)ethyl)piperazin-1-yl)benzo[b]thiophene-2-carbonitrile;

[0129]

[0130] (38) 5-fluoro-7-(4-(2-(2-oxo-1,2-dihydroquinolin-7-yl)ethyl)piperazin-1-yl)benzo[b]thiophene-2-carbonitrile;

[0131]

[0132] (39) 7-(2-(4-(6-fluorobenzo[d][1,3]dicyclopentadienyl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one;

[0133]

[0134] (40) 7-(2-(4-(6-fluorobenzo[d][1,3]bis(cyclopentadienyl)piperazin-1-yl)ethyl)quinolin-2(1H)-one;

[0135]

[0136] (41) 7-(2-(4-(6-fluorobenzofuran-4-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one-4,4-d2;

[0137]

[0138] (42) 7-(2-(4-(6-fluoro-2,3-dihydrobenzofuran-4-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one-4.4-d2;

[0139]

[0140] (43) 7-(2-(4-(6-fluorobenzofuran-4-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one-3,3,4,4-d4;

[0141]

[0142] (44)-(2-(4-(6-fluoro-2,3-dihydrobenzofuran-4-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one-3,3,4,4-d4;

[0143]

[0144] (45) 7-(2-(4-(6-fluorobenzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-4-hydroxy-3,4-dihydroquinolin-2(1H)-one;

[0145]

[0146] (45-1) R-7-(2-(4-(6-fluorobenzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-4-hydroxy-3,4-dihydroquinolin-2(1H)-one;

[0147]

[0148] (45-2) S-7-(2-(4-(6-fluorobenzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-4-hydroxy-3,4-dihydroquinolin-2(1H)-one;

[0149]

[0150] The compounds of the present invention have 5-HT 1A The multi-target effects on receptors and monoamine transporters are better in drugability than the compounds in patent application WO2015131856A1, and can be used to treat various central nervous system diseases, especially depression, bipolar disorder, schizophrenia, anxiety, phobia, autism, Alzheimer's disease, bipolar disorder, hysteria, obsessive-compulsive disorder, ADHD and other diseases.

[0151] According to a second aspect of the present invention, a method for preparing a quinolinone compound represented by general formula (I) is provided. The preparation method can be carried out by one of the following methods 1-2.

[0152] Method 1:

[0153] The compound represented by formula (II) or its salt is subjected to N-alkylation reaction with the compound represented by formula (III) or its salt, as shown in reaction formula 1:

[0154]

[0155] in, X, Y, W, Z, R6, R7, R8 and R9 are as defined and preferred above;

[0156] X1 represents a leaving group, such as halogen, C1-C6 alkylsulfonyloxy, benzenesulfonyloxy, naphthylsulfonyloxy, and the above C1-C6 alkylsulfonyloxy, benzenesulfonyloxy, naphthylsulfonyloxy may be further substituted with one or more groups selected from halogen, hydroxyl, amino, nitro, C1-C6 alkyl, C1-C6 alkoxy and C1-C6 alkanoyl;

[0157] X1 is preferably halogen, C1-C4 alkylsulfonyloxy, benzenesulfonyloxy, naphthylsulfonyloxy, and the above C1-C4 alkylsulfonyloxy, benzenesulfonyloxy, naphthylsulfonyloxy may be optionally further substituted with one or more selected from halogen, hydroxyl, amino, nitro, C1-C4 alkyl, C1-C4 alkoxy and C1-C4 alkanoyl;

[0158] X1 is most preferably chlorine, bromine, methanesulfonyloxy, trifluoromethanesulfonyloxy, benzenesulfonyloxy, naphthalenesulfonyloxy, toluenesulfonyloxy, nitrobenzenesulfonyloxy, aminobenzenesulfonyloxy, chlorobenzenesulfonyloxy, bromobenzenesulfonyloxy and methoxybenzenesulfonyloxy.

[0159] The N-alkylation reaction between the compound represented by formula (II) or a salt thereof and the compound represented by formula (III) or a salt thereof is carried out in the presence or absence of a solvent, or in the presence or absence of a base. The solvent includes water; ethers, such as dioxane, tetrahydrofuran, ethyl ether, methyl tert-butyl ether, diisopropyl ether, diethylene glycol dimethyl ether, ethylene glycol dimethyl ether, etc.; aromatics, such as benzene, toluene, xylene, nitrobenzene, chlorobenzene, etc.; alcohols, such as methanol, ethanol, isopropanol, butanol, tert-butanol, ethylene glycol; ketones, such as acetone, methyl ethyl ketone, 4-methyl-2-pentanone, etc.; amides, such as N,N-dimethylformamide, N,N-dimethylacetamide, 1-methyl-2-pyrrolidone, etc.; halogenated hydrocarbons, such as chloroform, dichloromethane, dichloroethane, carbon tetrachloride; esters, such as ethyl acetate, ethyl formate, methyl acetate, isopropyl acetate; others, such as dimethyl sulfoxide, acetonitrile, etc.; or mixtures of the above solvents.

[0160] The base can be selected from inorganic bases or organic bases. The inorganic bases include alkali metal hydroxides, such as sodium hydroxide, potassium hydroxide, cesium hydroxide, and lithium hydroxide; alkali metal carbonates, such as sodium carbonate, potassium carbonate, cesium carbonate, and lithium carbonate; alkali metal bicarbonates, such as sodium bicarbonate, potassium bicarbonate, and lithium bicarbonate; alkali metals, such as potassium and sodium; others, such as sodium amide, potassium amide, sodium hydride, and potassium hydride; organic bases include sodium methoxide, sodium ethoxide, potassium methoxide, potassium ethoxide, sodium acetate, trimethoate, and sodium hydride. Ethylamine, pyridine, diisopropylamine, diisopropylethylamine, tripropylamine, diethylamine, pyrimidine, quinoline, piperidine, piperazine, imidazole, dimethylaminopyridine, trimethylamine, N-ethyldiisopropylamine, N-methylmorpholine, dimethylaniline, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), 1,4-diazabicyclo[2.2.2]octane (DABCO). These bases can be used alone or in combination of two or more.

[0161] If necessary, the above reaction may be carried out by adding an alkali metal iodide such as potassium iodide and sodium iodide as a reaction accelerator.

[0162] The above reaction is usually carried out at room temperature to 200°C, preferably at room temperature to 150°C, and the reaction is usually completed in about 1 to 30 hours, preferably in 5 to 20 hours.

[0163] Method 2:

[0164] The compound represented by formula (IV) or its salt is coupled with the compound represented by formula (V) or its salt, as shown in Reaction Formula 2:

[0165]

[0166] in, X, Y, W, Z, R6, R7, R8 and R9 are as defined and preferred above;

[0167] X2 represents halogen or trifluoromethanesulfonyloxy, preferably bromine, iodine, chlorine or trifluoromethanesulfonyloxy;

[0168] The coupling reaction is carried out in the presence of a palladium catalyst and a base, in the presence or absence of a solvent.

[0169] The palladium catalyst is selected from palladium acetate (Pd(OAc)2), bis(triphenylphosphine)palladium dichloride ((Ph3P)2PdCl2), bis(benzonitrile)palladium chloride ((PhCN)2PdCl2), tetrakis(triphenylphosphine)palladium (Pd(PPh3)4), bis(triphenylphosphine)palladium acetate ((Ph3P)2Pd(OAc)2), 1,2-bis(diphenylphosphino)ethanepalladium dichloride ((PdCl2(dppe)2 )), bis(1,2-bis(diphenylphosphino)ethane)palladium (Pd(dppe)2), bis(dibenzylideneacetone)palladium (Pd(dba)2), tris(dibenzylideneacetone)dipalladium (Pd2(dba)3), [1,3-bis(diphenylphosphino)propane]dichloropalladium (PdCl2(dippp)) and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium (Pd(dppf)Cl2) One or more.

[0170] The base is one or more selected from sodium bis(trimethylsilyl)amide, potassium tert-butoxide, sodium tert-butoxide, cesium carbonate, potassium phosphate, sodium phosphate, sodium methoxide, sodium ethoxide, potassium hydroxide, sodium hydroxide, potassium fluoride, sodium fluoride, tetrabutylammonium fluoride (TBAF), sodium acetate, potassium acetate, cesium carbonate, potassium carbonate and sodium carbonate.

[0171] The solvent is not particularly limited as long as it does not interfere with the reaction, and includes water; ethers, such as dioxane, tetrahydrofuran, etc.; aromatic hydrocarbons, such as toluene, xylene, etc.; alcohols, such as tert-butyl alcohol, etc.; ketones, such as acetone, etc.; amides, such as N,N-dimethylformamide, etc.; others, such as dimethyl sulfoxide, acetonitrile, etc.; or a mixture of the above solvents.

[0172] If necessary, a suitable ligand can be added as a reaction promoter to carry out the above reaction. Suitable ligands are 2,2′-diphenylphosphino-1,1′-binaphthyl (BINAP), tri-tert-butyl (P(t-Bu)3), 1,1′-di-(diphenylphosphino)ferrocene (dppf), 2-dicyclohexylphosphino-2,4,6-triisopropylbiphenyl (x-phos), 4,5-bis-diphenylphosphino-9,9-dimethylxanthene (Xantphos), tri-tert-butylphosphine tetrafluoroborate and tri(2-methylphenyl)phosphine (P(o-tolyl)3).

[0173] The compounds of formula (II), formula (III), formula (IV) and formula (V) are commercially available compounds or are prepared according to methods known in the art or according to the synthesis methods of similar compounds.

[0174] The starting compound used in each of the above reaction formulas may be a suitable salt, and the suitable salt includes alkali metal salts and alkaline earth metal salts, such as sodium salts, potassium salts, calcium salts, magnesium salts, etc.; organic base salts, such as pyridinium salts, triethylamine salts, etc.; inorganic acid salts, such as hydrochlorides, hydrobromides, hydroiodides, sulfates, nitrates, phosphates, etc.; organic acid salts, such as formates, acetates, propionates, glycolates, oxalates, malonates, succinates, fumarates, maleates, lactates, malates, citrates, tartrates, picrates, glutamates, methanesulfonates and benzenesulfonates, etc.;

[0175] Furthermore, the starting compounds used in the above reaction formulae may include solvate forms such as hydrates, alcoholates, and the like.

[0176] The quinolinone compound represented by the general formula (I) of the present invention and its stereoisomers also include their solvate forms, such as hydrates, alcoholates, etc., and the solvates are included in the scope of the present invention.

[0177] The pharmaceutically acceptable salts of the quinolinone compounds and stereoisomers thereof represented by the general formula (I) of the present invention refer to the quinolinone compounds or stereoisomers represented by the general formula (I) treated with appropriate acids to convert them into therapeutically active non-toxic addition salt forms. The salts include hydrochloride, hydrobromide, hydroiodide, sulfate or bisulfate, nitrate, phosphate or acid phosphate, perchlorate, format, acetate, trifluoroacetate, propionate, pyruvate, glycolate, oxalate, malonate, succinate, glutarate, maleate, fumarate, lactate, malate, citrate, tartrate, picrate, glutamate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, salicylate, ascorbate, camphorate or camphorsulfonate, etc. On the contrary, the salt form can also be converted into the free base form by alkali treatment.

[0178] The term "pharmaceutically acceptable salts" used above also includes their solvates, and the solvates are included in the scope of the present invention. Examples of solvates include, for example, hydrates, alcoholates, and the like.

[0179] Each target compound obtained from each reaction formula can be separated and purified from the reaction mixture by the following methods, for example: after the reaction mixture is cooled, the crude product is separated by methods such as filtration, extraction or concentration, and then purified by conventional methods such as column chromatography, slurrying or recrystallization.

[0180] According to the third aspect of the present invention, there is also provided a pharmaceutical composition comprising a therapeutically effective amount of the quinolinone compound represented by the above general formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, and an optional pharmaceutically acceptable carrier.

[0181] According to a fourth aspect of the present invention, there is also provided a method for preparing a pharmaceutical composition, comprising mixing the quinolinone compound represented by the above general formula (I), its stereoisomer or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable carrier.

[0182] In the pharmaceutical composition of the present invention, a variety of pharmaceutical preparation forms can be selected according to the therapeutic purpose, including but not limited to: tablets, pills, capsules, granules, suspensions, solutions, creams, ointments, powders, suppositories, aerosols and injections (such as fat-soluble or oil-soluble injections), etc.

[0183] According to a fifth aspect of the present invention, there is also provided a use of the quinolinone compound represented by the general formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, or the pharmaceutical composition in the preparation of drugs for preventing and / or treating central nervous system diseases.

[0184] According to the sixth aspect of the present invention, there is also provided a method for treating and / or preventing central nervous system diseases, which comprises administering to humans or animals the quinolinone compound represented by the above general formula (I), its stereoisomers or pharmaceutically acceptable salts thereof.

[0185] The above-mentioned central nervous system diseases are selected from: schizophrenia; affective disorders; psychotic disorders; mood disorders; bipolar I disorder; bipolar II disorder; depression; dysthymic disorder; cyclothymic disorder; panic disorder; obsessive-compulsive disorder; impulsive disorder; post-traumatic stress disorder; anxiety disorder; hysteria; anorexia nervosa; sleep disorder; adjustment disorder; cognitive disorder; autism; nervous headache; mania; Parkinson's disease; Huntington's disease; various dementias; memory disorders; ADHD; attention deficit / hyperactivity disorder and tics, etc.

[0186] Preferably, the above central nervous system disease is selected from: refractory, intractable or chronic schizophrenia; intrinsic depression; major depression; refractory depression; panic attack; social phobia; acute stress disorder; Alzheimer's disease.

[0187] The compounds of the present invention have the following beneficial effects:

[0188] 1) The compounds of the present invention have a good inhibitory effect on 5-HT transporters and can be used to treat various central nervous system diseases.

[0189] 2) The compounds of the present invention have an effect on 5-HT 1A The receptor has a good regulatory effect, EC 50 or IC 50 Reaching the level of 0.1 to 10 nM, it can be used to treat various central nervous system diseases without causing complete excitation of 5-HT 1A Central or peripheral side effects caused by receptors.

[0190] 3) The compounds of the present invention are not only highly active, but also orally effective (high bioavailability), and have the characteristics of low effective dose and small toxic and side effects. They are effective in treating diseases in the central nervous system, especially major depressive disorder (MDD), anxiety, negative symptoms of schizophrenia, cognitive dysfunction, Parkinson's disease, ADHD and the like.

[0191] In summary, compared with the compounds disclosed in the prior art, the compounds of the present invention have the advantages of multi-target effects, lower effective doses, fewer toxic side effects, better safety and tolerability, etc., have good comprehensive drugability, and have good clinical application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0192] Figure 1 The results of the forced swimming test of Test Example 5 are shown, wherein * indicates P<0.05, and ** indicates P<0.01 (tested by one-way analysis of variance). DETAILED DESCRIPTION

[0193] The following preparation examples, examples and pharmacological activity test examples further illustrate the present invention, but do not limit the scope of the present invention.

[0194] Unless otherwise specified, the raw materials, reagents, methods, etc. used in the embodiments and experimental examples are conventional raw materials, reagents, methods in the art.

[0195] Preparation Example

[0196] Example 1 Preparation of 7-(2-(4-(6-fluorobenzofuran-4-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one

[0197]

[0198] (1) Synthesis of compound 1-b:

[0199] Under nitrogen protection, 3-fluoro-5-bromophenol (6g, 1eq), 2-bromo-1,1-dimethoxyethane (7.44g, 1.4eq) and potassium carbonate (6.51g, 1.5eq) were dissolved in 50ml DMF. The mixture was heated to 100°C and stirred overnight. The reaction solution was poured into water, extracted three times with ethyl acetate (EA), and the organic phase was washed twice with saturated sodium bicarbonate. The organic phase was dried and concentrated to obtain compound 1-b, 10.7g of brown-red oil, with a yield of >99%.

[0200] (2) Synthesis of compound 1-c:

[0201] Under nitrogen protection, 1-b (10.7 g, 1 eq) and polyphosphoric acid (PPA) (38 g, 3 eq) were dissolved in toluene and heated under reflux at 110°C for 2 h. The reaction solution was poured into water, and the organic phase was washed with water 2-3 times, and then washed with saturated sodium bicarbonate aqueous solution 1-2 times. The organic phase was dried, concentrated, and column chromatography was performed to obtain compound 1-c, 4.734 g of oil, with a yield of 57%.

[0202] (3) Synthesis of Compound 1-d

[0203] Under nitrogen protection, 1-c (4.734 g, 1 eq), tris(dibenzylidene indeneacetone)dipalladium (Pd2(dba)3) (1.8 g, 0.1 eq), potassium tert-butoxide (6.16 g, 2.5 eq), 1,1′-binaphthyl-2,2′-bisdiphenylphosphine (BINAP) (1.25 g, 0.1 eq) and 1-Boc-piperazine (4.9 g, 1.2 eq) were dissolved in toluene. The mixture was refluxed at 100°C and the reaction progress was monitored by TLC. After the reaction was completed, the mixture was filtered. The filtrate was concentrated and column chromatography was performed to obtain compound 1-d, a yellow oil of 1.604 g, with a yield of 22%.

[0204] (4) Synthesis of Compound 1-e

[0205] Dissolve 1-d (800 mg, 1 eq) in 2 ml of ethanol, add 2M ethanolic hydrogen chloride solution (5 ml), stir overnight at room temperature, concentrate under reduced pressure to remove the solvent, add isopropyl acetate to slurry, filter, and dry the filter cake to obtain compound 1-e, 600 mg of yellow solid (hydrochloride salt form), yield 93%.

[0206] (5) Synthesis of Compound 1

[0207] 1-e (600 mg, 1 eq), 1-f (823 mg, 1.3 eq), sodium bicarbonate (1 g, 5.0 eq), sodium iodide (360 mg, 1 eq), and DMF (6 mL) were added to a 50 mL single-mouth bottle, and the mixture was reacted at 80°C overnight under nitrogen protection. Water was added and stirred, and EA was extracted twice. The organic phase was dried, concentrated under reduced pressure, and purified by column chromatography to obtain 710 mg of the product.

[0208] 1 H NMR (400MHz, DMSO-d6) δ10.07 (s, 1H), 7.96 (d, J=2.3Hz, 1H), 7.13-7.08 (m, 2H), 7.04 (d, J=2.2Hz, 1H), 6.85 (dd, J=7.6, 1.7Hz, 1H), 6.79 (d, J=1.7Hz, 1H), 6.59 (d d, J=12.5, 2.2Hz, 1H), 3.24 (t, J=4.7Hz, 4H), 2.87 (t, J=7.5Hz, 2H), 2.77-2.68 ( m, 6H), 2.63-2.59 (m, 2H), 2.48 (dd, J=8.5, 6.5Hz, 2H). ESI-MS (m / z): 394.3[M+H] +

[0209] Example 2 Preparation of 7-(2-(4-(6-fluoro-2,3-dihydrobenzofuran-4-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one

[0210]

[0211] (1) Synthesis of Compound 2-a

[0212] Dissolve 1-d (0.437 g, 1 eq) in 5 ml methanol, add 5% palladium carbon (40 mg, 10% wt), pressurize with hydrogen to 2.5 MPa, stir overnight at 40°C, filter and concentrate the filtrate, and then column chromatograph to obtain compound 2-a, 302 mg of light yellow solid, with a yield of 68%.

[0213] (2) Synthesis of Compound 2-b

[0214] 2-a (302 mg, 1 eq) was dissolved in 5 ml of ethanol, 2M hydrogen chloride ethanol solution (8 ml) was added, and the mixture was stirred at room temperature overnight. The mixture was concentrated under reduced pressure to remove the solvent, and isopropyl acetate was added to make a pulp, filtered, and the filter cake was dried to obtain compound 2-b, 156 mg of a yellow solid (hydrochloride salt form), with a yield of 64%.

[0215] (3) Synthesis of Compound 2

[0216] Add 2-b (200 mg, 1.0 eq), 1-f (340 mg, 1.5 eq), DMF (6 mL), sodium bicarbonate (378 mg, 5.0 eq), sodium iodide (140 mg, 1.0 eq) to a 25 mL three-necked flask under nitrogen protection. Heat to 80 ° C and stir to react overnight. Add water, extract with EA twice, combine the organic phases, dry, concentrate under reduced pressure, and purify by column chromatography to obtain 200 mg of the product.

[0217] 1 H NMR (400MHz, DMSO-d6) δ10.01 (s, 1H), 7.06 (d, J=7.6Hz, 1H), 6.78 (dd, J=7.6, 1.7Hz, 1H), 6.71 (d, J=1.7Hz, 1H), 6.27-6.18 (m, 2H), 4.52 (t, J=8.5 Hz, 2H), 3.08-2.99 (m, 6H), 2.82 (t, J=7.5Hz, 2H), 2.67 (t, J=7.7Hz, 2H), 2.56-2.54(m, 6H), 2.42(dd, J=8.5, 6.5Hz, 2H).ESI-MS(m / z): 394.3[M+H] +

[0218] Example 9 Preparation of 5-(2-(4-(6-fluorobenzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-1,1a,3,7b-tetrahydro-2H-cyclopropyl[c]quinolin-2-one

[0219]

[0220] (1) Preparation of compound 9-b

[0221] Compound 9-a (10 g, 1.0 eq), potassium persulfate (28.3 g, 2.0 eq), copper sulfate pentahydrate (1.3 g, 0.1 eq) were added to acetonitrile (100 mL) and water (100 mL), heated to 80 ° C and stirred for 3 hours. The reaction solution was cooled to room temperature, extracted with methyltetrahydrofuran, the organic phase was dried, concentrated to dryness under reduced pressure, 50 mL of ethanol was added for 30 min, filtered, and the filter cake was dried to obtain compound 9-b, 3.6 g of yellow solid.

[0222] (2) Preparation of compound 9-c

[0223] Compound 9-b (3.6 g, 1.0 eq) was added to N, N-dimethylformamide (DMF) (36 mL), cooled to 0 ° C under nitrogen protection and stirred, and NaH (3.0 g, 4.0 eq) was slowly added. After adding, the mixture was stirred for 1 hour. P-methoxybenzyl chloride (PMBCl) (12.0 g, 4.0 eq) was slowly added. After adding, the mixture was heated to room temperature and reacted for 3 hours. Water was slowly added to the reaction solution, extracted with ethyl acetate, and the organic phase was dried and purified by column chromatography to obtain compound 9-c, 2.4 g of a yellow solid.

[0224] (3) Synthesis of Compound 9-d

[0225] Trimethylsulfoxide iodide (5.1 g, 10.0 eq) was added to tetrahydrofuran (THF) (50 mL), cooled to 0°C under nitrogen protection, and n-butyllithium (9.3 mL, 10.0 eq) was slowly added. After addition, the mixture was kept warm for 30 min. Compound 9-c (1.0 g, 1.0 eq) / THF (5 mL) was slowly added. After addition, the mixture was heated to 70°C and reacted for 3 hours. Water was added to the reaction solution, extracted with ethyl acetate, and the organic phase was dried and concentrated to dryness under reduced pressure to obtain compound 9-d, 1 g of a yellow solid.

[0226] (4) Synthesis of Compound 9-e

[0227] Compound 9-d (1.0 g, 1.0 eq) was added to trifluoroacetic acid (10 mL) and stirred at 70°C for 3 hours. The reaction solution was directly concentrated under reduced pressure to remove the solvent, quenched by adding amine methanol solution, filtered, the mother liquor was concentrated, and purified by column chromatography to obtain compound 9-e, 320 mg of off-white solid.

[0228] (5) Synthesis of Compound 9-f

[0229] Compound 9-e (320 mg, 1.0 eq) and triethylamine (TEA) (230 mg, 1.5 eq) were added to dichloromethane (DCM) (3 mL), and a solution of methanesulfonic anhydride (320 mg, 1.2 eq) / DCM (2 mL) was slowly added dropwise at 0°C, and stirred at room temperature for 0.5 hours. The reaction solution was quenched with water, and 20 mL of n-heptane was added and stirred to precipitate a solid, which was filtered and dried to obtain compound 9-f, 280 mg of an off-white solid.

[0230] (6) Synthesis of Compound 9

[0231] Compound 9-f (100 mg, 1.0 eq), compound 9-g (130 mg, 1.1 eq), potassium carbonate (120 mg, 2.0 eq) were added to acetonitrile (3 mL), heated to 80°C and stirred for 13 hours. The reaction solution was quenched with water, and a solid precipitated, which was filtered and dried to obtain compound 9, 125 mg of an off-white solid.

[0232] 1 H NMR (400MHz, DMSO-d6) δ9.89 (s, 1H), 7.67 (d, J = 5.5Hz, 1H), 7.51 (d, J = 8.8Hz, 1H ), 7.38 (d, J = 5.6Hz, 1H), 7.28 (d, J = 7.7Hz, 1H), 6.90-6.79 (m, 1H), 6.80-6.71 (m, 2H), 3.11(s, 4H), 2.72-2.68(m, 6H), 2.59-2.55(m, 2H), 2.50-2.47(m, 1H), 2.00- 1.95 (m, 1H), 1.58-1.53 ​​(m, 1H), 0.48 (q, J=4.7Hz, 1H).ESI-MS (m / z): 422.1[M+H] + .

[0233] Example 10 Preparation of 5-(2-(4-(5-fluorobenzo[b]thiophen-7-yl)piperazin-1-yl)ethyl)-1,1a,3,7b-tetrahydro-2H-cyclopropyl[c]quinolin-2-one

[0234]

[0235] (1) Synthesis of Compound 10-b

[0236] Under nitrogen protection, compound 10-a (5.0 g, 1.0 eq), ethyl thioglycolate (2.7 g, 1.0 eq), and potassium carbonate (6.2 g, 2.0 eq) were added to DMF (50 mL) and stirred at 60° C. for 2 hours. 150 mL of water was added to quench the reaction, and an off-white solid was precipitated, which was filtered, dried, and recrystallized by adding ethanol, filtered, and dried to obtain compound 10-b as an off-white solid (4.7 g, yield 69%).

[0237] (2) Synthesis of Compound 10-c

[0238] Compound 10-b (4.0 g, 1.0 eq) and sodium hydroxide (1.0 g, 2.0 eq) were added to a mixed solvent of THF (50 mL), methanol (15 mL) and water (20 mL), and stirred at room temperature for 12 hours. The organic phase was concentrated under reduced pressure, and 1 M HCl was added to adjust the pH to 2-3, and an off-white solid was precipitated, which was filtered and dried to obtain compound 10-c as an off-white solid (3.4 g, yield 94%).

[0239] (3) Synthesis of Compound 10-d

[0240] Under nitrogen protection, compound 10-c (3.4 g, 1.0 eq) and cuprous oxide (5.4 g, 3.0 eq) were added to N,N-dimethylformamide (30 mL), and the mixture was stirred at 145° C. for 6 hours. The reaction solution was filtered, purified water was added to the filtrate, stirred at room temperature for crystallization, filtered, and the filter cake was dried to obtain compound 10-d as a yellow solid (0.8 g).

[0241] (4) Synthesis of Compound 10-e

[0242] Under nitrogen protection, compound 10-d (400 mg, 1.0 eq), N-Boc piperazine (480 mg, 1.5 eq), 1,1′-binaphthyl-2,2′-bis(diphenylphosphine) (BINAP) (108 mg, 0.1 eq), Pd2(dba)3 (159 mg, 0.1 eq), potassium tert-butoxide (388 mg, 2.0 eq) were added to toluene (10 ml), and the mixture was stirred at 100° C. for 12 hours. The mixture was filtered, the filtrate was concentrated under reduced pressure, and the organic phase was purified by column chromatography to obtain compound 10-e as an off-white solid (220 mg).

[0243] (5) Synthesis of Compound 10-f

[0244] Compound 10-e (220 mg, 1.0 eq) was dissolved in 2 ml of ethanol, 2M hydrogen chloride ethanol solution (5 ml) was added, and stirred at room temperature overnight. After the organic phase was concentrated, water was added to adjust the pH to 7-8, extracted with ethyl acetate, dried, and concentrated under reduced pressure to obtain compound 10-f, 150 mg of a yellow solid.

[0245] (6) Synthesis of Compound 10

[0246] Compound 9-f (100 mg, 1.0 eq), compound 10-f (130 mg, 1.1 eq), and potassium carbonate (120 mg, 2.0 eq) were added to acetonitrile (3 mL), heated to 80°C, and stirred for 13 hours. The reaction solution was quenched with water, and a solid precipitated, which was filtered and dried to obtain 50 mg of an off-white solid product.

[0247] 1H NMR (400MHz, DMSO-d6) δ9.88 (s, 1H), 7.82 (d, J = 5.4Hz, 1H), 7.42 (d, J = 5.4Hz, 1H), 7. 35 (dd, J=9.1, 2.3Hz, 1H), 7.27 (d, J=7.7Hz, 1H), 6.85-6.81 (m, 2H), 6.73 (d, J=1.6Hz, 1H), 3.19 (t, J=4.7Hz, 4H), 2.71-2.64 (m, 6H), 2.58-2.54 (m, 2H), 2.50-2.47 (m, 1H), 2 .00-1.94(m, 1H), 1.58-1.52(m, 1H), 0.48(q, J=4.7Hz, 1H).ESI-MS(m / z): 422.2[M+H] + .

[0248] The following table shows the compounds of Examples 3 to 8 and 11 to 45. These compounds can be prepared by the same method as in the above examples except that starting materials and intermediates corresponding to the final products are used.

[0249] For the compound of Example 45, isomers 45-1 and 45-2 were chirally separated by HPLC, wherein the chromatographic conditions were:

[0250] Chromatographic columns CHIRAL PAK IC 4.6×250mm, 5μm Mobile phase A n-Hexane Mobile phase B 0.1% diethylamine (isopropanol as diluent) Isocratic elution Mobile phase A: mobile phase B = 80: 20 Detection wavelength 210nm Column temperature 35℃ Flow rate 1.0ml / min Injection volume 5μl Run time 40min Sample concentration 1.0mg / ml (ethanol as diluent)

[0251]

[0252]

[0253]

[0254]

[0255]

[0256]

[0257]

[0258]

[0259]

[0260] Test Example 1. 5-HT 1A Receptor agonist activity test

[0261] The compounds were tested for their effects on recombinant human 5-HT cells using LANCETM cAMP 384 Kit (PerkinElmer, USA). 1A 5-HT receptor in CHO-K1 cells 1A The inhibitory effect of the test compounds on cAMP production in CHO-K1 cells was used to evaluate the 5-HT receptor agonism. 1A Receptor agonism. 8-OH-DPAT was used as a positive control. The specific operation is as follows:

[0262] a) Compounds (test compounds and positive control) were prepared with DMSO to a storage concentration of 10 mM for later use, and Forskolin was prepared with a storage concentration of 10 mM for later use. The starting concentration of 8-OH-DPAT was 1 μM, 3X dilution. The starting concentration of the test compound was 0.1 μM, 3X dilution, and each concentration was repeated 2 times. Use Echo to transfer 100 nL of compound and 10 nL of Forskolin to the test plate, and the final DMSO concentration was <1%.

[0263] b) 5-HT 1A Take the stable cell line out of the incubator and observe the cell status. When the cell density reaches 80% to 90%, discard the culture medium and wash the cells with 5mL DPBS. Remove DPBS, add 2mL trypsin, and place in a 37℃ carbon dioxide incubator for 2-5min. Add 10mL complete culture medium to collect the cells, centrifuge at 1000rpmX4 min, and discard the supernatant. Use Stimulation Buffer (HBSS+5mM HEPES+0.5mM IBMX+0.1%BSA) to adjust the cell suspension to a density of 1000cells / well.

[0264] c) Transfer 10 μl of the prepared cell solution to the test plate with the compound.

[0265] d) Centrifuge at 600 rpm for 3 minutes and incubate at room temperature for one hour.

[0266] e) Add 5 μL 4X Eu-cAMP tracer solution and 5 μL 4X ULight TM -anti-cAMP solution, centrifuge at 600 rpm for 3 minutes, and incubate at room temperature for one hour.

[0267] f) Read the data using the multifunctional microplate reader EnVision, EC 50 The results were calculated using Graphpad Prism software and are shown in Table 1.

[0268] Table 1:

[0269]

[0270]

[0271] *Note: The compound of Example 85 in patent application WO2015131856A1 (7-(2-(4-(6-fluorobenzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one).

[0272] As can be seen from the above table, the compounds of Examples 1-3, 5, 12, 14-16 of the present invention and the control compound have comparable 5-HT 1A Receptor agonist activity.

[0273] Test Example 2. 5-HT transporter inhibitory activity test

[0274] Neurotransmitter transporter uptake assay kit (Molecular devices) was used to test the transporter inhibition of HEK-293 cells expressing human SERT. The test was performed according to the method in the kit manual, and citalopram was used as a positive control. The specific operation is as follows:

[0275] a) HEK-hSERT cells were seeded into 384-well plates at 20,000 cells / well and then transferred to an incubator and incubated at 37°C overnight.

[0276] b) The next day, dilute the compounds (test compounds and positive control) from 20 mM DMSO solution to working concentrations with DMSO. Transfer each test compound and citalopram to a 384-well plate using assay buffer containing 0.1% BSA. The starting concentration of citalopram is 1 μM, 3X dilution. The starting concentration of the test compound is 10 μM, 4X dilution, and each concentration is repeated 2 times.

[0277] c) Take out the cell culture 384-well plate from the incubator, aspirate the culture medium from the wells, and add the test compound solution at 25 μL / well. Incubate at 37°C for 30 min. After the incubation is completed, add 25 μL of the dye solution to each well and incubate at 37°C for 30 min.

[0278] d) The fluorescence values ​​were read on Flexstation 3 and the data were analyzed using Graphpad Prism. The results are shown in Table 2.

[0279] Table 2:

[0280]

[0281]

[0282] *Note: The compound of Example 85 in patent application WO2015131856A1.

[0283] As can be seen from the above table, both the example compounds of the present invention and the control compounds have strong 5-HT transporter inhibitory activity, especially when Y in the general formula is an oxygen atom, the 5-HT transporter inhibitory activity of the compounds is better.

[0284] Test Example 3. Pharmacokinetics experiment in mice

[0285] Animals: Male ICR mice. Animals were randomly assigned to treatment groups and fasted for 12 h before dosing.

[0286] Drugs: The compound was dissolved in a solvent (0.5% CMC-Na). The intravenous (iv) dose was 0.3 mg / kg, and the administration volume was 5 ml / kg; the oral (po) dose was 1 mg / kg, and the administration volume was 10 mL / kg body weight.

[0287] Sample collection and bioanalysis: After administration, blood was collected from the mouse orbits at 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, and 24 h (n = 3 at each time point) and placed in EP tubes containing sodium heparin. The mice were immediately killed by dislocation after blood collection, and the mouse brains at the corresponding time points were removed. All samples were immediately collected, quickly frozen, and stored at -70°C for future use.

[0288] Plasma samples were obtained by centrifugation of whole blood, and 10 μL of plasma was mixed with 190 μL of internal standard solution (20 ng / mL metolazone dissolved in acetonitrile containing 0.1% formic acid). After mixing, centrifugation was performed at 13,000 rpm for 10 min, and 120 μL of supernatant was taken from each sample. Then 0.5-10 μL (depending on the sensitivity of the compound) was taken out for drug analysis using a liquid chromatography-tandem mass spectrometry (LC-MS / MS) method suitable for the purpose. The standard of each analyte was used for calibration and identification.

[0289] According to the ratio of brain tissue: extract (50% acetonitrile water) = 1 (g): 8 (ml), 5 3mm magnetic beads were used for homogenization at 3.2m / s for 2min in an OMNI Bead Ruptor 24 Elite homogenizer, and centrifuged at 4°C and 3000g for 3min. 50uL of the supernatant was taken, 200uL of internal standard solution (20ng / mL dissolved in 80% acetonitrile water) was added and mixed, and then centrifuged at 13000rpm for 10min. 120μL of supernatant was taken from each sample, and then 0.5-10μl (depending on the sensitivity of the compound) of the supernatant was taken out for analysis using an appropriate LC-MS / MS method. The standard of each analyte was used for calibration and identification.

[0290] Data Analysis: Drug concentrations below the lower limit of quantitation (LLOQ) were recorded as zero. Pharmacokinetic data were analyzed in PK Solver using a non-compartmental, bolus, or extravascular infusion analysis model. Data points below the LLOQ were not included in the analysis to improve t 1 / 2 The pharmacokinetic parameters in plasma are shown in Table 3. max The data are shown in Table 4:

[0291] Table 3

[0292]

[0293]

[0294] Table 4

[0295] Compound <![CDATA[C max (po)(of / of)]]> Compound of Example 1 368 Compound of Example 2 413 Reference compound* 254

[0296] *Note: The compound of Example 85 in patent application WO2015131856A1.

[0297] As shown in Tables 3 and 4 above, the compounds of Examples 1-2 of the present invention have higher oral maximum blood drug concentration and bioavailability in mice than the control compound. After oral administration of 1 mg / kg, the compounds of the present invention have better brain penetration in mice than the control compound, and the concentration in the brain is higher.

[0298] Test Example 4. Pharmacokinetics experiment in rats

[0299] The compound of Example 2 was used for in vivo pharmacokinetic experiments in rats (non-fasting SD male rats). The compound of the present invention was dissolved in a solvent (0.5% CMC-Na). The intravenous (iv) dose was 1 mg / kg, and the administration volume was 5 ml / kg; the oral (po) dose was 3 mg / kg, and the administration volume was 10 mL / kg body weight. After administration, about 0.3 mL of blood samples were collected from the jugular vein of the rats at the blood collection points: 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, and 24 h (n=3 at each time point). The collected blood was stored under ice cooling, and the plasma was quickly separated by centrifugation and a precipitant was added. The concentration of the compound to be tested was quantified by LCMS. The experimental results are shown in Table 5 below:

[0300] Table 5

[0301]

[0302] *Note: The compound of Example 85 in patent application WO2015131856A1.

[0303] As can be seen from the above table, the compound of Example 2 of the present invention has higher oral maximum blood drug concentration and bioavailability in rats than the control compound.

[0304] Test Example 5. Forced Swim Test:

[0305] Drug: The compound of the present invention and the positive control compound (vortioxetine) were mixed with 5% DMSO and then added Mix HS15 and add 90% saline to prepare a solution of appropriate concentration for immediate use.

[0306] Animals: Male C57 mice, about 22 g. The animals were randomly divided into a blank control group and each test drug group, with 8 animals in each group. The mice in each group were intraperitoneally injected with the solvent prescription or each test drug.

[0307] Experimental steps: 0.5h after administration, mice were subjected to forced swimming test. The water level in the forced swimming device was 45cm and the water temperature was 25℃. The mice were placed in the experimental room to adapt to the environment for 1h before the experiment. At the beginning of the experiment, the mice were placed in the device for 6min. The whole process was recorded with a camera. When analyzing the data, only the last 4min of the immobility time of the mice was counted. The compounds of the present invention showed significant antidepressant-like effects in the dosage range of 0.01 to 0.1mg / kg, and the onset dose was low. In particular, if Figure 1 As shown, both compound 2 (0.01 mg / kg dose) and the positive control vortioxetine (10 mg / kg dose) can significantly reduce the immobility time of mice compared with the vehicle control group, and have an antidepressant-like effect.

Claims

1. A quinolinone compound represented by the general formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof: in: X on the benzene ring is a halogen; Y is NH, O or S; W is CH, CH2 or O; represents a single or double bond; When W is CH2 or O, the represents a single bond; when W is CH, represents a double bond; Z on the heterocyclic ring is hydrogen, cyano, amino C1-C6 alkanoyl or amino C1-C6 alkyl substituted with C1-C6 alkyl; When connected with R6, R7, R8, R9 When it represents a single bond, R6, R7, R8, and R9 are each independently selected from hydrogen, deuterium, halogen, methyl, ethyl, hydroxyl, amino, or acetylamino; or one of R6 and R7 and one of R8 and R9 and the two carbon atoms connected thereto form a 3-6 membered carbocyclic ring, and the other two are as defined above; When connected with R6, R7, R8, R9 When it represents a double bond, R6 and R8 are each independently selected from hydrogen, deuterium, halogen, methyl, ethyl, hydroxyl, amino or acetylamino, and R7 and R9 do not exist; or R6 and R8 and the two carbon atoms connected thereto form a 3-6 membered carbon ring, and R7 and R9 do not exist; Provided that the following compounds are not included: 1) 7-(2-(4-(6-fluorobenzothiophen-4-yl)piperazin-1-yl)ethyl)-quinolin-2(1H)-one; 2) 7-(2-(4-(6-fluorobenzothiophen-4-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one.

2. The quinolinone compound represented by the general formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: X is F; and / or Y is O or S; and / or Z is hydrogen, cyano, amino C1-C4 acyl or amino C1-C4 alkanoyl substituted by C1-C4 alkyl (preferably N-methylcarbamoyl); preferably, Z is hydrogen, cyano, N-methylcarbamoyl or carbamoyl; and / or Connected to R6, R7, R8, R9 represents a single bond, R6, R7, R8, R9 are each independently selected from hydrogen, deuterium, halogen or hydroxyl; or R6 and R8 and the two carbon atoms connected to them form a 3-membered carbocyclic ring, R7 and R9 are hydrogen or deuterium; or R6, R7, R8, R9 connected to represents a double bond, R6 and R8 are each independently selected from hydrogen, deuterium, halogen or hydroxyl, and R7 and R9 do not exist.

3. The quinolinone compound represented by the general formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: represents a single or double bond; X is a halogen; Y is O or S; W is CH, CH2 or O; Z is hydrogen, cyano, carbamoyl or carbamoyl substituted by a C1-C6 alkyl group; When connected with R6, R7, R8, R9 When it represents a single bond, R6, R7, R8, and R9 are each independently selected from hydrogen, deuterium, halogen, methyl, ethyl, hydroxyl, amino, or acetylamino; or one of R6 and R7 and one of R8 and R9 and the two carbon atoms connected thereto form a 3-6 membered carbocyclic ring, and the other two are as defined above; When connected with R6, R7, R8, R9 When it represents a double bond, R6 and R8 are each independently selected from hydrogen, deuterium, halogen, methyl, ethyl, hydroxyl, amino or acetylamino, preferably hydrogen, deuterium, halogen, and R7 and R9 do not exist; or R6 and R8 and the two carbon atoms to which they are connected form a 4-6 membered carbocyclic ring, and R7 and R9 do not exist.

4. The quinolinone compound represented by the general formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: represents a single or double bond; X is F; Y is O; W is CH, CH2 or O; Z is hydrogen, cyano, carbamoyl or carbamoyl substituted by a C1-C6 alkyl group; When connected with R6, R7, R8, R9 When it represents a single bond, R6, R7, R8, and R9 are each independently selected from hydrogen, deuterium, halogen, methyl, ethyl, hydroxyl, amino, or acetylamino; or one of R6 and R7 and one of R8 and R9 and the two carbon atoms connected thereto form a 3-6 membered carbocyclic ring, and the other two are as defined above; When connected with R6, R7, R8, R9 When it represents a double bond, R6 and R8 are each independently selected from hydrogen, deuterium, halogen, methyl, ethyl, hydroxyl, amino or acetylamino, preferably hydrogen, deuterium, halogen, and R7 and R9 do not exist; or R6 and R8 and the two carbon atoms to which they are connected form a 4-6 membered carbocyclic ring, and R7 and R9 do not exist.

5. The quinolinone compound represented by general formula (I) according to any one of claims 1 to 4, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The quinolinone compound represented by general formula (I) is selected from the following structures: in, Z, R6, R7, R8 and R9 are as defined in claims 1-4 respectively.

6. The quinolinone compound represented by general formula (I) according to any one of claims 1 to 4, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The quinolinone compound represented by general formula (I) is selected from the following structures: Alternatively, the quinolinone compound represented by general formula (I) is selected from the following structures: in, Z, R6, R7, R8 and R9 are as defined in claims 1-4 respectively.

7. The quinolinone compound represented by the general formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The quinolinone compound represented by the general formula (I) is selected from the following compounds or pharmaceutically acceptable salts thereof: (1) 7-(2-(4-(6-fluorobenzofuran-4-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one; (2) 7-(2-(4-(6-fluoro-2,3-dihydrobenzofuran-4-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one; (3) 7-(2-(4-(5-fluorobenzofuran-7-yl)piperazin-1-yl)ethyl)quinolin-2(1H)-one; (4) 7-(2-(4-(5-fluoro-2,3-dihydrobenzofuran-7-yl)piperazin-1-yl)ethyl)quinolin-2(1H)-one; (5) 7-(2-(4-(5-fluoro-2,3-dihydrobenzofuran-7-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one; (6) 7-(2-(4-(5-fluorobenzofuran-7-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one; (7) 7-(2-(4-(6-fluoro-2,3-dihydrobenzofuran-4-yl)piperazin-1-yl)ethyl)quinolin-2(1H)-one; (8) 7-(2-(4-(6-fluorobenzofuran-4-yl)piperazin-1-yl)ethyl)quinolin-2(1H)-one; (9) 5-(2-(4-(6-fluorobenzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-1,1a,3,7b-tetrahydro-2H-cyclopropyl[c]quinolin-2-one; (10) 5-(2-(4-(5-fluorobenzo[b]thiophen-7-yl)piperazin-1-yl)ethyl)-1,1a,3,7b-tetrahydro-2H-cyclopropyl[c]quinolin-2-one; (11) 7-(2-(4-(5-fluorobenzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one; (12) 7-(2-(4-(7-fluorobenzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one; (13) 7-(2-(4-(4-fluorobenzo[b]thiophen-7-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one; (14) 7-(2-(4-(6-fluorobenzo[b]thiophen-7-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one; (15) 7-(2-(4-(5-fluorobenzo[b]thiophen-7-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one; (16) 7-(2-(4-(5-fluorobenzo[b]thiophen-7-yl)piperazin-1-yl)ethyl)quinolin-2(1H)-one; (17) 7-(2-(4-(6-fluorobenzofuran-4-yl)piperazin-1-yl)ethyl)-4-hydroxy-3,4-dihydroquinolin-2(1H)-one; (18) 7-(2-(4-(6-fluoro-2,3-dihydrobenzofuran-4-yl)piperazin-1-yl)ethyl)-4-hydroxy-3,4-dihydroquinolin-2(1H)-one; (19) 7-(2-(4-(6-fluorobenzofuran-4-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one-3,4-d2; (20) 7-(2-(4-(6-fluorobenzofuran-4-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one-3,3-d2; (21) 7-(2-(4-(6-fluoro-2,3-dihydrobenzofuran-4-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one-3.4-d2; (22) 7-(2-(4-(6-fluoro-2,3-dihydrobenzofuran-4-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one-3,3-d2; (23) 6-fluoro-4-(4-(2-(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)ethyl)piperazin-1-yl)benzo[b]thiophene-2-carboxamide; (24) 6-fluoro-4-(4-(2-(2-oxo-1,2-dihydroquinolin-7-yl)ethyl)piperazin-1-yl)benzo[b]thiophene-2-carboxamide; (25) 6-fluoro-4-(4-(2-(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)ethyl)piperazin-1-yl)benzofuran-2-carboxamide; (26) 6-fluoro-4-(4-(2-(2-oxo-1,2-dihydroquinolin-7-yl)ethyl)piperazin-1-yl)benzofuran-2-carboxamide; (27) 6-fluoro-N-methyl-4-(4-(2-(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)ethyl)piperazin-1-yl)benzo[b]thiophene-2-carboxamide; (28) 7-(2-(4-(5-fluorobenzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)quinolin-2(1H)-one; (29) 7-(2-(4-(7-fluorobenzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-quinolin-2(1H)-one; (30) 7-(2-(4-(4-Fluorobenzo[b]thiophen-7-yl)piperazin-1-yl)ethyl)-quinolin-2(1H)-one; (31) 7-(2-(4-(6-fluorobenzo[b]thiophen-7-yl)piperazin-1-yl)ethyl)-quinolin-2(1H)-one; (32) 6-fluoro-N-methyl-4-(4-(2-(2-oxo-1,2-dihydroquinolin-7-yl)ethyl)piperazin-1-yl)benzo[b]thiophene-2-carboxamide; (33) 5-fluoro-7-(4-(2-(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)ethyl)piperazin-1-yl)benzo[b]thiophene-2-carboxamide; (34) 5-fluoro-7-(4-(2-(2-oxo-1,2-dihydroquinolin-7-yl)ethyl)piperazin-1-yl)benzo[b]thiophene-2-carboxamide; (35) 5-fluoro-7-(4-(2-(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)ethyl)piperazin-1-yl)benzofuran-2-carboxamide; (36) 5-fluoro-7-(4-(2-(2-oxo-1,2-dihydroquinolin-7-yl)ethyl)piperazin-1-yl)benzofuran-2-carboxamide; (37) 5-fluoro-7-(4-(2-(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)ethyl)piperazin-1-yl)benzo[b]thiophene-2-carbonitrile; (38) 5-fluoro-7-(4-(2-(2-oxo-1,2-dihydroquinolin-7-yl)ethyl)piperazin-1-yl)benzo[b]thiophene-2-carbonitrile; (39) 7-(2-(4-(6-fluorobenzo[d][1,3]dicyclopentadienyl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one; (40) 7-(2-(4-(6-fluorobenzo[d][1,3]bis(cyclopentadienyl)piperazin-1-yl)ethyl)quinolin-2(1H)-one; (41) 7-(2-(4-(6-fluorobenzofuran-4-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one-4,4-d2; (42) 7-(2-(4-(6-fluoro-2,3-dihydrobenzofuran-4-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one-4.4-d2; (43) 7-(2-(4-(6-fluorobenzofuran-4-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one-3,3,4,4-d4; (44)-(2-(4-(6-fluoro-2,3-dihydrobenzofuran-4-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one-3,3,4,4-d4; (45) 7-(2-(4-(6-fluorobenzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-4-hydroxy-3,4-dihydroquinolin-2(1H)-one; (45-1) R-7-(2-(4-(6-fluorobenzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-4-hydroxy-3,4-dihydroquinolin-2(1H)-one; (45-2) S-7-(2-(4-(6-fluorobenzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-4-hydroxy-3,4-dihydroquinolin-2(1H)-one; 8. A method for preparing a quinolinone compound represented by the general formula (I) according to any one of claims 1 to 7, the preparation method being carried out by one of the following methods 1 to 2: Method 1: The compound represented by formula (II) or its salt is subjected to N-alkylation reaction with the compound represented by formula (III) or its salt, as shown in reaction formula 1: in, X, Y, R6, R7, R8 and R9 have the same definitions as in the corresponding claims; X1 represents a leaving group, such as halogen, C1-C6 alkylsulfonyloxy, benzenesulfonyloxy, naphthylsulfonyloxy, and the above C1-C6 alkylsulfonyloxy, benzenesulfonyloxy, naphthylsulfonyloxy may be further substituted with one or more groups selected from halogen, hydroxyl, amino, nitro, C1-C6 alkyl, C1-C6 alkoxy and C1-C6 alkanoyl; Preferably, the reaction is carried out in the presence or absence of a solvent, or in the presence or absence of a base; The reaction temperature is from room temperature to 200°C, and the reaction time is from 1 to 30 hours; Method 2: The compound represented by formula (IV) or its salt is coupled with the compound represented by formula (V) or its salt, as shown in Reaction Formula 2: in, X, Y, W, Z, R6, R7, R8 and R9 have the same definitions as in the corresponding claims; X2 represents halogen or trifluoromethanesulfonyloxy; Preferably, the reaction is carried out in the presence of a palladium catalyst and a base, or in the presence or absence of a solvent; Preferably, the reaction temperature is from room temperature to 200° C., and the reaction time is from 1 to 30 hours.

9. A pharmaceutical composition comprising a therapeutically effective amount of a quinolinone compound represented by the general formula (I) selected from any one of claims 1 to 7, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, and an optional pharmaceutically acceptable carrier.

10. Use of the quinolinone compound represented by the general formula (I) according to any one of claims 1 to 7, its stereoisomers or pharmaceutically acceptable salts thereof, or the pharmaceutical composition according to claim 9 in the preparation of a medicament for preventing and / or treating a central nervous system disease; Preferably, the central nervous system disease is selected from the group consisting of: schizophrenia; affective disorder; psychotic disorder; mood disorder; bipolar I disorder; bipolar II disorder; depression; dysthymic disorder; cyclothymic disorder; panic disorder; obsessive-compulsive disorder; impulsive disorder; post-traumatic stress disorder; anxiety disorder; hysteria; anorexia nervosa; sleep disorder; adjustment disorder; cognitive disorder; autism; neuralgic headache; mania; Parkinson's disease; Huntington's disease; various dementias; memory disorders; ADHD; attention deficit / hyperactivity disorder and tics; More preferably, the central nervous system disease is selected from: refractory, intractable or chronic schizophrenia; intrinsic depression; major depression; refractory depression; panic attack; social phobia; acute stress disorder; Alzheimer's disease.

Images